General Information of Drug (ID: DMDHGPN)

Drug Name
Aminooxazole carboxamide derivative 1 Drug Info
Synonyms PMID27774822-Compound-Figure6Example25
Cross-matching ID
TTD Drug ID
DMDHGPN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Janus kinase 2 (JAK-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Momelotinib DMF98Q0 Myelofibrosis 2A20.2 Approved [2]
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [3]
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [4]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [5]
Fedratinib DM4ZBK6 Myelofibrosis 2A20.2 Approved [6]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [7]
XL019 DMJ6F5C Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [8]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [9]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Janus kinase 3 (JAK-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [11]
Ritlecitinib DMYKNME Alopecia areata ED70.2 Approved [12]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [13]
VX-509 DM2U3MX Rheumatoid arthritis FA20 Phase 2/3 [3]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [12]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [14]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [15]
TD-8236 DMTOMJN Asthma CA23 Phase 2 [16]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [17]
SNA-125 DM8L1GJ Atopic dermatitis EA80 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Janus kinase 1 (JAK-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [3]
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [4]
Upadacitinib DM32B5U Rheumatoid arthritis FA20 Approved [18]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [19]
SHR0302 DMUL8ZT Ulcerative colitis DD71 Phase 3 [20]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [12]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [9]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [19]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [12]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting TYK2 tyrosine kinase (TYK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deucravacitinib DMAR1YS Plaque psoriasis EA90.0 Approved [12]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [12]
PF-06826647 DM5H8V1 Plaque psoriasis EA90.0 Phase 2 [12]
PF-06826647 DM5H8V1 Plaque psoriasis EA90.0 Phase 2 [21]
NDI-034858 DM2FJE7 Psoriatic arthritis FA21 Phase 2 [22]
Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ N. A. N. A. Patented [23]
PMID27774824-Compound-Figure9Example2down DMXAV42 N. A. N. A. Patented [23]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [23]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [23]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [23]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [1]
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [1]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [1]
TYK2 tyrosine kinase (TYK2) TTBYWP2 TYK2_HUMAN Inhibitor [1]

References

1 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
2 Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
3 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
4 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
5 National Cancer Institute Drug Dictionary (drug id 609888).
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
7 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
8 Company report (Portola Pharmaceuticals)
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
14 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
15 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
16 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
17 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
20 Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
21 Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
22 Clinical pipeline report, company report or official report of Nimbus Therapeutics
23 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.